Briggs Morrison - Sep 19, 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
President, Head of R&D, Director
Signature
/s/ Michael A. Metzger, Attorney-in-fact
Stock symbol
SNDX
Transactions as of
Sep 19, 2022
Transactions value $
-$2,123,587
Form type
4
Date filed
9/21/2022, 04:18 PM
Previous filing
Sep 16, 2022
Next filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $1.25M +114K +641.06% $10.90 132K Sep 19, 2022 Direct
transaction SNDX Common Stock Sale -$2.63M -114K -86.51% $23.03 17.8K Sep 19, 2022 Direct F1, F2
transaction SNDX Common Stock Options Exercise $650K +59.6K +334.43% $10.90 77.5K Sep 20, 2022 Direct
transaction SNDX Common Stock Sale -$1.39M -59.6K -76.98% $23.25 17.8K Sep 20, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -114K -100% $0.00* 0 Sep 19, 2022 Common Stock 114K $10.90 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -59.6K -100% $0.00* 0 Sep 20, 2022 Common Stock 59.6K $10.90 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 774,958 options to purchase shares of common stock that are vested and immediately exercisable and a total of 370,042 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $22.50 to $23.35
F3 The sale prices ranged from $22.60 to $23.75
F4 This option is fully vested.